Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 1996
OBJECTIVES: I. Evaluate the efficacy of chimeric monoclonal antibody (cA2) compared with placebo in closure of enterocutaneous fistulae in patients with Crohn\'s disease.
Epistemonikos ID: 80790cb4b7ae4c0d25cd05f31f49977fb920f404
First added on: May 03, 2024